Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden

New England Journal of Medicine

Volumn 360, Issue 19, 2009, Pages 1933-1945

  James, Stefan K ^a   Stenestrand, Ulf ^b   Lindbäck, Johan ^a   Carlsson, Jörg ^c   Scherstén, Fredrik ^c   Nilsson, Tage ^d   Wallentin, Lars ^a   Lagerqvist, Bo ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c Länssjukhuset Kalmar ^*  (Sweden)

^d Karlstad Lasarett   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYPHER; CYPHER SELECT; ENDEAVOR; FIBRINOGEN RECEPTOR ANTAGONIST; PACLITAXEL; RAPAMYCIN; TAXUS EXPRESS; TAXUS LIBERTE; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ADULT; AGED; ARTICLE; BARE METAL STENT; CAUSE OF DEATH; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RESTENOSIS; RISK ASSESSMENT; SWEDEN; THERAPY EFFECT; COMPARATIVE STUDY; EVALUATION; MIDDLE AGED; MORTALITY; RISK; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY RESTENOSIS; CORONARY STENOSIS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT (HEALTH CARE); RISK; STENTS; SWEDEN;

EID: 65649146754     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0809902     Document Type: Article

References (27)

1. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel- eluting coronary stents. N Engl J Med 2007;356:998-1008. (Pubitemid 46376800)
2. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:1030-1039 (Pubitemid 46376803)
3. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:989-997 (Pubitemid 46376799)
4. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370:937-948 (Pubitemid 47393576)
5. Tu JV, Bowen J, Chiu M, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 2007;357:1393-1402 (Pubitemid 47541971)
6. Mauri L, Silbaugh TS, Wolf RE, et al. Long-term clinical outcomes after drugeluting and bare-metal stenting in Massachusetts. Circulation 2008;118:1817-1827
7. Marzocchi A, Saia F, Piovaccari G, et al. Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. Circulation 2007;115:3181-3188 (Pubitemid 47012232)
8. Jensen LO, Maeng M, Kaltoft A, et al. Stent thrombosis, myocardial infarction, and death after drug-eluting and baremetal stent coronary interventions. J Am Coll Cardiol 2007;50:463-470 (Pubitemid 47088133)
9. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369:667-678 (Pubitemid 46281313)
10. Lagerqvist B, James SK, Stenestrand U, Lindbäck J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-1019 (Pubitemid 46376801)
11. Flynn MR, Barrett C, Cosio FG, et al. The Cardiology Audit and Registration Data Standards (CARDS), European data standards for clinical cardiology practice. Eur Heart J 2005;26:308-313 (Pubitemid 40227433)
12. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
13. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983;1:710-719 (Pubitemid 14202071)
14. Brunner-La Rocca HP, Kaiser C, Bernheim A, et al. Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivitäts Trial (BASKET): an 18-month analysis. Lancet 2007;370:1552-1559 (Pubitemid 350018894)
15. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 1999;319:1492-1495
16. R Development Core Team. A language and environment for statistical computing. Vienna: R-Foundation for Statistical Computing, 2006. (Accessed April 13, 2009, at http://www.R-project.org.)
17. Lemos PA, Hoye A, Goedhart D, et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study. Circulation 2004;109:1366-1370 (Pubitemid 38387822)
18. Williams DO, Abbott JD, Kip KE. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: report of the DEScover Registry. Circulation 2006;114:2154-2162 (Pubitemid 44747896)
19. Kastrati A, Dibra A, Spaulding C, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J 2007;28:2706-2713 (Pubitemid 350139205)
20. Schömig A, Dibra A, Windecker S, et al. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel- eluting stents in patients with coronary artery disease. J Am Coll Cardiol 2007;50:1373-1380 (Pubitemid 47449734)
21. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-2130 (Pubitemid 40617065)
22. Doyle B, Rihal CS, O'Sullivan CJ, et al. Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation 2007;116:2391-2398 (Pubitemid 350145074)
23. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus baremetal stents. J Am Coll Cardiol 2006;48:2584-2591 (Pubitemid 44881238)
24. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297:159-168 (Pubitemid 46089732)
25. Ong AT, Serruys PW, Aoki J, et al. The unrestricted use of paclitaxel- versus sirolimus- eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol 2005;45:1135-1141 (Pubitemid 40432449)
26. Ong AT, van Domburg RT, Aoki J, Sonnenschein K, Lemos PA, Serruys PW. Sirolimus-eluting stents remain superior to bare-metal stents at two years: medium-term results from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol 2006;47:1356-1360
27. Lemos PA, Arampatzis CA, Saia F, et al. Treatment of very small vessels with 2.25-mm diameter sirolimus-eluting stents (from the RESEARCH registry). Am J Cardiol 2004;93:633-636 (Pubitemid 38293077)